A single unvalidated manufacturing process can result in product recalls, regulatory shutdowns, and patient harm. Manufacturing process validation is the documented, scientific approach that proves a production process consistently delivers output meeting predetermined quality standards. Without it, manufacturers risk batch failures, regulatory action, and harm to end users.
Whether in pharmaceutical production, medical device manufacturing, food processing, or automotive assembly, production process validation is not optional. It is a regulatory expectation and a business imperative. Organizations that invest in structured validation programs reduce waste, accelerate time to market, and maintain regulator and patient trust.
8 of the world’s top 10 life sciences companies trust Kneat to digitalize and streamline validation. This article covers the three lifecycle stages, three validation types, regulatory frameworks, common challenges, and emerging trends shaping modern manufacturing process validation.
What is manufacturing process validation and why does it matter?
Manufacturing process validation is the collection of activities that establish scientific evidence proving a process can consistently produce high-quality products. It spans the entire product lifecycle — from initial process design through commercial production and ongoing monitoring.
In life sciences manufacturing, process validation safeguards patient safety and maintains uniform product quality and efficacy. It also drives cost efficiency, waste reduction, market competitiveness, and regulatory compliance. Without process validation, manufacturers lack the controls needed to produce safe, effective, and reliable products. This is why manufacturing process validation is a regulatory and operational necessity.
Safeguarding patient safety
The primary objective in manufacturing is to create products that are safe and effective for patients. A faulty manufacturing process can introduce variability or defects in the finished product, putting patients at risk. Process validation acts as a safeguard against these risks by assessing and confirming each stage of the production process. This scrutiny ensures that every product is reliable and safe for use.
Uniformity in product quality and efficacy
In pharmaceutical manufacturing, variations in product quality can have serious consequences. Even small deviations in the manufacturing process may result in differences in the efficacy, safety, and overall quality of drugs. Process validation plays a critical role in establishing and maintaining consistent quality. It does so by identifying Critical Process Parameters (CPPs) and ensuring they remain within predefined limits. This consistency is essential for building and preserving patient confidence.
Cost efficiency and waste reduction
Effective manufacturing processes go beyond quality assurance — they also drive cost optimization. Process validation can identify areas of resource waste or inefficiency. By refining processes, companies reduce waste, conserve resources, and improve the cost-effectiveness of production.
Market competitiveness
In a rapidly evolving life sciences landscape, manufacturers that consistently deliver high-quality products hold a competitive advantage. Process validation enables companies to meet and exceed quality benchmarks. This makes their products more attractive to consumers and healthcare providers.
Regulatory compliance
Life sciences manufacturing is one of the most heavily regulated industries globally. Regulatory bodies impose strict requirements to ensure product quality and patient safety. These include the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. The pharmaceutical industry in particular faces multi-layered regulatory obligations across every stage of manufacturing.
Compliance with these regulations is not optional — it is a legal obligation. Process validation is the means by which companies demonstrate their commitment to meeting these requirements. For a deeper look at the regulatory landscape, see the regulatory frameworks section below.
The three stages of manufacturing process validation
The FDA’s lifecycle approach to process validation defines three distinct stages. Each stage builds on the previous one, creating a continuous cycle of design, qualification, and verification. Together, they form the foundation of modern manufacturing process validation and align with current process validation guidelines.
- In stage one (process design), manufacturers gain knowledge on their process through development and scale-up activities.
- In stage two (process qualification), the team confirms that the process design reproduces commercial manufacturing consistently.
- In stage three, Continued Process Verification (CPV) provides ongoing assurance during routine production that the process remains in a state of control.
The FDA outlined this three-stage lifecycle model in its Guidance for Industry: Process Validation: General Principles and Practices. It replaced earlier approaches that treated validation as a one-time event. The lifecycle approach recognizes that manufacturing processes evolve and require continuous oversight.
Stage one — process design
Process design is the first stage of manufacturing process validation. In this stage, manufacturers define the commercial manufacturing process and build the scientific foundation for qualification and ongoing control. The goal is to understand the process well enough to identify which parameters to control and how.
Key activities in process design include:
- Teams identify Critical Quality Attributes (CQAs), the physical, chemical, biological, or microbiological properties that must fall within defined limits.
- Engineers define Critical Process Parameters (CPPs), the process inputs that directly affect CQAs and require monitoring and control.
- The design space maps the range of input variables and process parameters demonstrated to provide quality assurance.
- Risk assessments use tools such as Failure Mode and Effects Analysis (FMEA) to identify and prioritize process risks before qualification.
Process design also includes developing the Validation Master Plan (VMP). The VMP outlines the overall validation strategy, scope, responsibilities, and acceptance criteria for the entire manufacturing process. It serves as the governing document for all subsequent validation activities and is a core element of any process validation protocol.
A Quality by Design (QbD) approach strengthens process design by embedding quality into the process from the start. Rather than relying on end-product testing alone, QbD uses scientific understanding and risk assessment to design a process that consistently meets specifications. The FDA encourages QbD as part of its lifecycle framework. QbD aligns closely with International Council for Harmonisation (ICH) Q8 (Pharmaceutical Development) principles.
Manufacturers also define testing methods during this stage. Validated analytical methods ensure that the data collected during qualification and verification stages is accurate and reliable.
Stage two — process qualification
Process qualification is the second stage of manufacturing process validation. It confirms that the process design reproduces consistently at commercial scale. This stage involves qualifying the facility, equipment, and utilities — then demonstrating that the process performs as expected under real manufacturing conditions.
Process qualification follows a structured sequence of qualification activities:
- Installation Qualification (IQ) confirms that the team has correctly installed equipment, systems, and utilities and that they meet manufacturer specifications and design requirements.
- Operational Qualification (OQ) verifies that equipment operates within established parameters across its intended operating ranges. OQ also tests control functions, alarms, switches, and safety interlocks.
- Performance Qualification (PQ) demonstrates that the process consistently produces acceptable output under real production conditions, using commercial-scale materials and qualified operators.
After IQ, OQ, and PQ, manufacturers execute Process Performance Qualification (PPQ).
PPQ combines the qualified facility, equipment, and process to confirm that the manufacturing process performs reliably at commercial scale. During the PPQ batches, data will be collected testing the worst case scenario for processing to gain confidence prior to commercial manufacturing. PPQ protocols define the number of batches, sampling plans, and acceptance criteria. The FDA does not prescribe a fixed number of PPQ batches, however 3 batches is a common selection, Manufacturers must justify the quantity statistically based on process complexity, variability, and risk.
Manufacturing equipment validation is a critical input to process qualification. Unqualified equipment can compromise the entire validation effort, regardless of how well engineers designed the process.
In many manufacturing environments, process qualification also intersects with commissioning and qualification activities for new facilities, clean rooms, and utility systems. These activities establish that the manufacturing environment itself meets the process validation guidelines that commercial production demands.
Stage three — continued process verification
Continued Process Verification (CPV) is the third stage of manufacturing process validation. It provides ongoing assurance that the process remains in a state of control during routine commercial production. CPV is not a one-time check — it is a continuous program that runs for the life of the product.
Key CPV activities include:
- Quality teams monitor CPPs and CQAs using statistical process control (SPC) charts and trend analysis to detect drift before it causes out-of-specification product.
- Annual product reviews evaluate process performance, identify trends, and determine whether the process remains validated.
- Revalidation triggers events such as equipment changes, supplier changes, or adverse trend data that require re-evaluation. If revalidation is needed, Stage 2 – Process Qualification will be revisited.
- All monitoring records must meet ALCOA++ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available) principles.
CPV enables manufacturers to adapt to evolving requirements and challenges. It also connects directly to continuous process verification concepts and supports data-driven decision-making. For a deeper look at how CPV works in practice, see continuous process verification in manufacturing.
The three types of process validation
Regulatory frameworks also recognize three types of process validation. Regulatory frameworks classify these types by when validation activities occur relative to commercial production.
Prospective validation (premarket validation) takes place before a product reaches commercial distribution. It is the standard approach for new manufacturing processes. Prospective validation includes developing the validation protocol, executing qualification batches, and analyzing the resulting data. The process must meet all acceptance criteria before any product reaches the market.
Concurrent validation takes place during routine commercial production. It applies when manufacturers have limited prospective validation data. For example, a process change may require real-time monitoring of commercial batches to confirm the process remains in control. Concurrent validation must still follow a pre-approved protocol with defined acceptance criteria.
Revalidation occurs when significant changes affect the process, equipment, raw materials, or manufacturing facility. Data trends from CPV also trigger revalidation when they indicate the process may no longer operate in a validated state. Revalidation ensures that any change — planned or unplanned — does not compromise product quality.
These three types of process validation cover the full range of validation scenarios a manufacturing organization encounters. For a more detailed comparison, see types of process validation.
Regulatory frameworks for manufacturing process validation
Overlapping regulatory frameworks govern manufacturing process validation. Understanding these frameworks is essential for companies that manufacture and distribute products across multiple markets. The three most influential frameworks are the FDA lifecycle guidance, the EMA’s Annex 15, and the ICH harmonization guidelines.
FDA — process validation: general principles and practices (2011)
The FDA issued its current process validation guidance in 2011, replacing the 1987 version. The 2011 guidance introduced a three-stage lifecycle approach: Process Design, Process Qualification, and Continued Process Verification. This model now serves as the global benchmark for manufacturing process validation. The FDA expects ongoing verification throughout a product’s lifecycle, not just initial qualification at launch. For a detailed breakdown of the FDA’s requirements, see FDA process validation guidance.
EMA — Annex 15: qualification and validation
The European Medicines Agency (EMA) governs process validation through Annex 15 of the EU Guidelines to Good Manufacturing Practice (GMP). Annex 15 outlines requirements for qualification of equipment, utilities, and facilities, as well as process validation for pharmaceutical manufacturers operating in the EU. While the FDA’s lifecycle model focuses on three stages, Annex 15 places additional emphasis on formal qualification documentation and concurrent validation protocols. Companies manufacturing for both US and EU markets must satisfy both frameworks.
ICH Q8, Q9, and Q10
The International Council for Harmonisation (ICH) provides process validation guidelines that underpin both FDA and EMA requirements. ICH Q8 (Pharmaceutical Development) establishes the scientific foundation for process design, including the design space concept and Quality by Design. ICH Q9 (Quality Risk Management) provides the risk-based framework for prioritizing validation activities. ICH Q10 (Pharmaceutical Quality System) defines the quality system infrastructure needed to support the entire product lifecycle. Together, these three guidelines create the foundation for science-based and risk-based manufacturing process validation across global markets.
Common manufacturing process validation challenges
Even with clear regulatory frameworks, manufacturing organizations face practical challenges when executing and maintaining process validation programs. These challenges grow more acute in global operations with multiple sites, products, and regulatory jurisdictions.
Documentation burden
Paper-based validation systems generate enormous volumes of documents — protocols, execution records, deviation reports, and approval signatures. Manual documentation slows cycle times, increases the risk of transcription errors, and makes audit preparation time-consuming. Organizations running validation across dozens of products and multiple sites can spend thousands of labor hours on documentation alone. PCI Pharma Services, a contract development and manufacturing organization, reduced validation labor hours by 65% per GMP chamber. The team went from 26 to nine hours per chamber after replacing paper-based processes with Kneat Gx. Their throughput increased from six to 26 chamber validations per month. Read the full story: PCI client story.
Evolving regulatory expectations
The shift from one-time validation to a continuous lifecycle approach requires organizations to rethink how they resource and manage validation programs. Regulatory agencies now expect ongoing data collection, trend analysis, and periodic reassessment — not just a batch of qualification runs at launch. Teams that built their programs around the older “three batches and done” model must restructure processes, retrain staff, and invest in monitoring infrastructure.
Scaling validation across sites
Maintaining consistency across global manufacturing facilities is one of the most difficult operational challenges in manufacturing process validation. Different sites may use different equipment, operate under different regulatory jurisdictions, and employ teams with varying levels of validation experience. Standardizing protocols, templates, and approval workflows across 10, 20, or 50+ sites requires deliberate governance and digital infrastructure. MSD, for example, digitalized validation globally across 27 sites with Kneat Gx. The result: 60% cycle time reduction and 46% process steps eliminated on average. Read the full story: MSD client story.
Data integrity and ALCOA++ compliance
Regulators increasingly scrutinize data integrity during inspections. Every validation record must meet ALCOA++ standards. In paper-based or hybrid systems, maintaining ALCOA++ compliance across thousands of records is error-prone and difficult to audit. A single data integrity finding can trigger a warning letter or consent decree.
Legacy systems and integration
Many manufacturing sites operate older equipment, standalone instruments, and disconnected software systems. Connecting these legacy systems to a modern validation platform requires careful planning, validated interfaces, and often phased migration strategies. Maintaining data integrity and 21 CFR Part 11 compliance throughout adds further complexity. The integration challenge grows as manufacturers adopt real-time monitoring and digital execution.
For a deeper look at these obstacles and practical strategies for overcoming them, see process validation challenges and strategies for success.
Emerging trends in manufacturing process validation
Manufacturing process validation is evolving as new technologies reshape how manufacturers collect data, execute protocols, and maintain compliance. Real-time analytics, digital validation platforms, and automation are driving a shift toward Validation 4.0. This model mirrors the broader Pharma 4.0 movement. Two trends stand out: Process Analytical Technologies (PAT) and the digitalization of the validation lifecycle.
Process analytical technologies (PAT)
Process Analytical Technologies (PAT) uses advanced analytical tools to monitor, analyze, and control manufacturing processes in real time. Key PAT capabilities include:
- PAT uses spectroscopy, chromatography, and in-line sensors to collect data in real time and enable continuous process verification during manufacturing.
- Real-time monitoring flags process anomalies before they result in out-of-specification batches.
- Continuous data streams allow operators and quality teams to intervene immediately when parameters drift.
- PAT integrates with process control systems to adjust parameters automatically based on real-time measurements.
Digitalizing process validation
The digitalization of the validation lifecycle involves the integration of advanced digital technologies into the validation process. Moving from paper-based systems to a digital platform eliminates manual transcription and accelerates approval cycles. It also creates a single source of truth for all validation records.
Benefits of using a digital validation system such as Kneat Gx for process validation include:
- Kneat Gx keeps complete, searchable validation records available on demand for regulatory inspections.
- Automated workflows for test execution, review, and approval reduce cycle times and human error.
- Real-time dashboards give teams visibility into validation status, progress, and bottlenecks across sites and projects.
- Built-in 21 CFR Part 11/Annex 11 controls enforce ALCOA++ data integrity principles throughout the validation lifecycle.
- Stakeholders review and approve validation deliverables from any location, eliminating delays from physical document routing.
- Integration APIs connect validation data with laboratory information management, enterprise resource planning, maintenance management, and other manufacturing systems.
- Teams execute validation protocols directly in the system with guided steps, embedded calculations, and real-time data capture.
- The platform stores, controls, reviews, and approves all document files in one validated system.
Futureproof your process validation with Kneat Gx
Manufacturing process validation demands rigorous qualification and continuous verification across every site and product line. The right digital platform helps teams meet these requirements efficiently and build audit readiness into every project.
8 of the world’s top 10 life sciences companies trust Kneat Gx. Kneat Gx supports validation teams in regulated manufacturing environments. It brings efficiency and transparency to process validation. Its built-in 21 CFR Part 11 and Annex 11 compliance supports the move toward Pharma 4.0.
The manufacturers who validate with confidence are the ones who deliver quality products — reliably and on schedule.
Additional process validation resources
- Read the eBook: Understanding Process Validation.
- Download the guide: The Digital Process Validation Guide.
- Watch the on-demand webinar: Process Validation 4.0: Overcoming Process Validation Challenges With Technology.
FAQ
What are the three types of process validation?
The three types are prospective validation (performed before commercial distribution), concurrent validation (performed during routine production), and revalidation. Revalidation occurs when significant changes affect the process, equipment, or materials.
How do you validate a manufacturing process?
Follow the FDA’s three-stage lifecycle approach. Start with process design to define the process, then process qualification to confirm it works at commercial scale. Continued process verification then monitors the process throughout routine production.
What is the difference between IQ, OQ, and PQ?
Installation Qualification (IQ) confirms the team installed equipment correctly. Operational Qualification (OQ) verifies it operates within defined parameters. Performance Qualification (PQ) demonstrates it consistently produces acceptable output under real conditions. See IQ, OQ, PQ, and PPQ for a detailed breakdown.
Is process validation a one-time activity?
No. The FDA’s lifecycle model requires ongoing verification through Continued Process Verification (CPV). Validation is a continuous program, not a one-time checkpoint.
How many batches does process performance qualification (PPQ) require?
There is no fixed number, though 3 would be common. FDA guidance requires a statistically justified number of batches based on process risk, complexity, and variability.
What is the difference between process validation and product testing?
Product testing checks the quality of finished output. Process validation proves that the manufacturing process itself is capable of consistently producing quality output.
